| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
22026 |
| Drug |
Pembrolizumab |
| Brand |
Keytruda® |
| Indication |
Is indicated as monotherapy for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. |
| Rapid review commissioned |
22/04/2022 |
| Rapid review completed |
01/06/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/07/2022 |
| Pre-submission consultation with Applicant |
06/09/2022 |
| Full submission received from Applicant |
23/03/2023 |
| Preliminary review sent to Applicant |
08/12/2023 |
| NCPE assessment re-commenced |
18/01/2024 |
| Factual accuracy sent to Applicant |
11/04/2024 |
| NCPE assessment re-commenced |
18/04/2024 |
